Black Diamond Therapeutics Inc. (BDTX) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-02, Black Diamond Therapeutics Inc. (NASDAQ: BDTX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $1.86 (+1.64% 1D, market cap $106.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BDTX ranks #189 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BDTX carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 10.8%. By comparison, VYGR (Voyager Therapeutics Inc.) holds a E grade (15/100 RQD, P/E N/A, ROIC -35.0%, cap $108.4M) and LENZ (LENZ Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -27.8%, cap $109.7M). Among the 5-stock peer group, BDTX leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).
Per BDTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701541), Black Diamond Therapeutics Inc. generated $0 in revenue, $22.37B in net income, and $29.6M in free cash flow against $143.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 45.4 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 59/100 (C-) score, BDTX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.95) or 200D SMA ($2.19) invalidates the momentum regime and cuts Target Base ($1.87) toward Bear Floor ($1.46).
Black Diamond Therapeutics Inc. (BDTX) advanced +1.64% to $1.86, trading at 8% of its 52-week range ($1.6 – $4.94). Solid steady margins (11% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11 price target.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BDTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BDTX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Black Diamond Therapeutics Inc. (BDTX) ranks #189 by composite RQD confidence (59/100, grade C-) and #651 by equity capitalization ($106.9M). Within this direct 5-issuer industry benchmark cohort, BDTX leads on earnings valuation at N/A trailing P/E, while BDTX leads on capital efficiency and profitability with 10.8% ROIC and — gross margin. BDTX currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BDTX
ACTIVE
Black Diamond Therapeutics Inc. | C- | 59/100 | — | — | 10.8% | +1.64% | $106.9M | Benchmark Subject |
| VYGR Voyager Therapeutics Inc. | E | 15/100 | — | — | -35.0% | -4.35% | $108.4M | /vygr-vs-bdtx → |
| LENZ LENZ Therapeutics Inc. | D | 44/100 | — | 96.0% | -27.8% | +8.72% | $109.7M | /lenz-vs-bdtx → |
| ENGN enGene Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -3.16% | $102.5M | /engn-vs-bdtx → |
| TVGN Tevogen Inc. | D- | 40/100 | — | — | -35.0% | -3.04% | $95.2M | /tvgn-vs-bdtx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Black Diamond Therapeutics Inc. (BDTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $22.37B, operating cash flow of $29.6M, and free cash flow of $29.6M (+147.5% YoY). On the balance sheet, BDTX closed FY2025 with $143.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $22.37B | $29.6M | $29.6M | $143.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$69.68B | -$62.3M | -$62.3M | $122.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$82.4M | -$66.7M | -$66.7M | — | — |
As of 2026-11-02, Black Diamond Therapeutics Inc. (NASDAQ: BDTX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $1.86 (+1.64% 1D, market cap $106.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BDTX ranks #189 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BDTX carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 10.8%. By comparison, VYGR (Voyager Therapeutics Inc.) holds a E grade (15/100 RQD, P/E N/A, ROIC -35.0%, cap $108.4M) and LENZ (LENZ Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -27.8%, cap $109.7M). Among the 5-stock peer group, BDTX leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).
Per BDTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701541), Black Diamond Therapeutics Inc. generated $0 in revenue, $22.37B in net income, and $29.6M in free cash flow against $143.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BDTX last traded at $1.86 (+1.64% on volume of 551,021 shares), positioning the stock -4.62% below its 50-day simple moving average ($1.95) and -15.07% below its 200-day simple moving average ($2.19). Across its 52-week range of $1.60 to $4.94, BDTX sits at the 7.8% percentile with a 14-day RSI of 45.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.63 to $2.09).
Why BDTX Stock advanced +1.64% Today — RQD Quant Desk Flash. Solid steady margins (11% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).